source
- Health insurers grapple with profit cuts after a costly 2025, outlook for 2026 remains uncertainIn 2025, a wave of health insurers reduced or withdrew their profit forecasts after being hit by rising medical expenses. The cost pressures stemmed from higher drug prices, increased utilization…
- Analyst doubts gold-based ALS therapy from Clene, calling it ineffectiveAdam Feuerstein, a senior biotech writer, published a piece in his Biotech Scorecard newsletter questioning a new ALS treatment. The company Clene is developing CNM-Au8, which it describes as a hi…